Protocol Ledger

NCT04817761 · Phase II/III · TERMINATED

SPARK-ALL: Calaspargase Pegol in Adults With ALL

Interventional Phase II/III clinical trial protocol NCT04817761 sponsored by Institut de Recherches Internationales Servier in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-07-07 Enrollment: 42 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04817761
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)42 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04817761
Protocol FieldVerified Registry Value
NCT IdentifierNCT04817761
Consolidated Lead SponsorInstitut de Recherches Internationales Servier
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusTERMINATED
Registered Enrollment42 participants (ACTUAL)
Registered Start Date2021-07-07
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI